Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 337 · 2 trials · 7 indications
Adverse events and clinical laboratory abnormalities defined as DLTs.
Determine anti-tumor activity of AMG 337 in subjects with MET amplified gastric/gastroesophageal junction/esophageal adenocarcinoma (cohort 1)
| Arm | Type | Description |
|---|---|---|
| Single arm | EXPERIMENTAL | - |
| Dose Escalation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AMG 337 | DRUG | Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1) |
Inclusion Criteria: * Able to self administer daily AMG 337 as a whole capsule * Male or female 20 years of age or over * Phase 1: Subjects must have a pathologically confirmed, advanced solid tumor for which the subjects have received prior therapy for advanced disease, for which no standard thera...
AMG 337 is an investigational small molecule being studied for the treatment of stomach neoplasms and advanced malignancy. It is being developed by Amgen Inc. (AMGN) and is currently in Phase 1 clinical development.
AMG 337 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is an investigational small molecule in Phase 1 clinical development for oncology indications.
AMG 337 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed, and the drug remains under investigation for stomach neoplasms and advanced malignancy.
AMG 337 has been studied in two completed clinical trials. NCT01253707 was a Phase 1 study in 111 subjects with advanced solid tumors in the United States. NCT02096666 was a Phase 1/2 study in 11 Asian subjects with stomach neoplasms in Japan.
AMG 337 is a small molecule oncology drug. Its specific molecular target has not been disclosed in available information. The drug is being studied for its potential effects in stomach neoplasms and advanced malignancy.